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Rosuvastatin in Patients with Elevated C-Reactive Protein
To the Editor:  Ridker et al. (Nov. 20 issue) re-
port the results of Justification for the Use of Stat-
ins in Prevention: an Intervention Trial Evaluat-
ing Rosuvastatin (JUPITER),1 which showed that 
rosuvastatin significantly reduced cardiovascular 
events in patients with elevated levels of C-reac-
tive protein. However, broad application of their 
results in primary prevention is premature, since 
the baseline therapy that many patients in the study 
were receiving did not meet existing standards. 
Although about 50% of the patients had interme-
diate Framingham risk scores, which would have 
qualified such men (and possibly women) for as-
pirin therapy,2,3 only 16.6% of the patients were 
receiving aspirin. One quarter of the patients had 
a systolic blood pressure of at least 145 mm Hg, 
indicating that their hypertension was not being 
treated according to existing national goals.4 Al-
most 16% of the patients were current smokers.
It is impossible to tell how many of the pa-
tients were receiving “optimal therapy” at baseline, 
defined as meeting current targets in all three of 
the following areas: the use of aspirin when in-
dicated, hypertension treated to national goals, 
and no tobacco use. Future substudies should ex-
amine the number of patients who would need to 
be treated to prevent one cardiovascular event in 
the subgroup of patients who were already receiv-
ing optimal therapy at baseline. Public health 
might be better served by improving compliance 
with existing standards.
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To the Editor: JUPITER is notable for the unac-
knowledged exclusion of a population that may be 
at increased risk for dose-related adverse effects 
of rosuvastatin. In 2005, the label for Crestor was 
amended to read, “The result of a large pharma-
cokinetic study conducted in the U.S. demonstrat-
ed an approximate 2-fold elevation in median ex-
posure in Asian subjects (having either Filipino, 
Chinese, Japanese, Korean, Vietnamese or Asian-
Indian origin) compared with a Caucasian control 
group. This increase should be considered when 
making rosuvastatin dosing decisions for Asian 
patients.”1 Decreased activity of an organic an-
ion-transporting polypeptide, OATP1B1, may ac-
count for differences in the pharmacokinetics of 
rosuvastatin.2,3
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Although Ridker et al. state that “by design, 
the study population was diverse,” no Asian coun-
tries are included among the study sites, and the 
demographic breakdown of the 17,802 patients 
according to race or ethnic group includes only 
white, black, Hispanic, and “other or unknown.” 
It would appear that there may have been a con-
scious choice to exclude people of Asian descent 
from JUPITER. 
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To the Editor: Although the JUPITER study in-
vestigators report event rates for most individual 
components of the primary end point (nonfatal 
myocardial infarction, nonfatal stroke, hospitaliza-
tion for unstable angina, and revascularization), 
they do not report event rates for death from car-
diovascular causes, even though the trial was ter-
minated early in part because of apparent mortal-
ity benefits. We therefore attempted to calculate 
the rates of death from both cardiovascular and 
noncardiovascular causes from the numbers pro-
vided in the article.
On the basis of our calculations, in the rosuva-
statin group, as compared with the placebo group, 
the number of deaths from cardiovascular causes 
was not significantly reduced (31 vs. 37 deaths), 
although the number of deaths from any cause 
was significantly reduced (167 vs. 210 deaths). This 
finding is at odds with extensive data from pre-
vious statin trials. In addition, the authors suggest 
that their results support treating patients on the 
basis of elevations in C-reactive protein. However, 
they provide no results showing that C-reactive 
protein is an independent predictor of the relative 
or absolute benefit of therapy, since the treatment 
effects seen with rosuvastatin could have been 
mediated by reductions in low-density lipoprotein 
(LDL) cholesterol. Multivariable models that ad-
just for baseline levels of LDL cholesterol and 
changes in LDL cholesterol over time would fur-
ther clarify the role of C-reactive protein.
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To the Editor: Ridker et al. describe a modest 
but significant benefit from rosuvastatin, as com-
pared with placebo, in a large group of patients 
with LDL cholesterol levels of less than 130 mg 
per deciliter (3.4 mmol per liter) and high-sensi-
tivity C-reactive protein levels of 2 mg per liter or 
more. Although they state that there was no het-
erogeneity of results for subgroups of patients ac-
cording to sex, race or ethnic group, or known 
coronary risk factors, they did not make a similar 
statement regarding subgroups stratified accord-
ing to the baseline level of high-sensitivity C-reac-
tive protein or cholesterol, the very measures that 
are affected by the study intervention. 
Could the authors provide data showing wheth-
er there was a gradient of risk for cardiovascular 
events and death according to baseline levels of 
C-reactive protein or a gradient of benefit from 
rosuvastatin according to the extent of the base-
line elevation? Furthermore, could they reassure 
clinicians that there was no incremental risk 
among patients with the lowest baseline choles-
terol levels who were treated with a lipid-lower-
ing statin? Was the clinical benefit explained by 
changes in levels of C-reactive protein, and how 
could clinicians monitor the intervention in prac-
tice in order to achieve a clinical benefit?
Elizabeth R. Jenny-Avital, M.D.
Jacobi Medical Center 
Bronx, NY 10461 
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To the Editor: Ridker et al. do not adequately 
address the issue of the development of new-
onset diabetes in patients receiving rosuvastatin. 
Although this issue has not been systematically 
investigated, the risk of diabetes was increased by 
a factor of 1.25 (95% confidence interval [CI], 1.05 
to 1.51) among patients receiving rosuvastatin. 
The discordance of the effects of rosuvastatin on 
vascular outcomes and the risk of diabetes is per-
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plexing, particularly since the two conditions are 
believed to share a common inflammatory basis.1 
We therefore used the available published data from 
large-scale, placebo-controlled trials of statins to 
evaluate the relationship between statin therapy 
and incident diabetes.
Among 59,006 patients, the risk of diabetes 
for patients receiving a statin was similar to that 
for patients receiving placebo (relative risk, 1.06; 
95% CI, 0.91 to 1.23). The risk of diabetes appears 
to increase with increased potency of the lipid-
lowering agent. For the two large, placebo-con-
trolled trials of pravastatin, the West of Scotland 
Coronary Prevention Study (WOSCOPS) and the 
Long-Term Intervention with Pravastatin in Ische-
mic Disease (LIPID) study, the relative risk of dia-
betes in the pravastatin group was 0.81 (95% CI, 
0.64 to 1.02). For the two large, placebo-controlled 
trials of rosuvastatin, JUPITER and the Controlled 
Rosuvastatin Multinational Trial in Heart Failure 
(CORONA), the relative risk of diabetes in the ro-
suvastatin group was 1.22 (95% CI, 1.05 to 1.42). 
For drugs with intermediate potency, simvastatin 
and atorvastatin, the values fell in between these 
extremes.
Koon-Hou Mak, M.D.
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To the Editor: JUPITER was stopped early, after 
a median follow-up of 1.9 years. The number of 
patients who would need to be treated for 2 years 
to prevent the occurrence of one primary end point 
was 95. Ridker et al. extrapolate these results by 
a projection over a 5-year treatment period. This 
estimation should be viewed critically, since the 
study has most of the characteristics of a trun-
cated trial.
The majority of randomized clinical trials that 
are stopped early because of an observed benefit 
of the treatment under investigation are industry-
funded drug trials that are stopped at the first in-
terim analysis, with the results published in a 
high-impact medical journal. The hazard ratio of 
0.56 for the primary end point in JUPITER is close 
to the median risk ratio of 0.53 among 143 trun-
cated randomized trials.1 Truncated trials over-
estimate the treatment effect.2 This factor was 
important in the Candesartan in Heart Failure: 
Assessment of Reduction in Mortality and Mor-
bidity (CHARM) study, in which early stopping was 
resisted.3 Because rosuvastatin would be given 
long-term for primary prevention, the JUPITER 
study investigators should have continued follow-
up to determine whether the positive results would 
have continued or would have declined to a more 
modest effect.
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To the Editor: JUPITER was designed to continue 
until 520 confirmed primary end points had been 
documented. The study was terminated early be-
cause of the efficacy of rosuvastatin. However, the 
statistical results are reported as if the trial had 
been designed as a fixed-length trial with 393 pri-
mary end points, even though the analysis was 
sequential. This leads to bias in the reporting.
The correct P value for the sequential analysis, 
as conducted, is P<0.05, not P<0.00001, as report-
ed. In addition, the point estimate of the treatment 
effect from a trial that was terminated early for 
efficacy is biased in favor of the treatment.1 Thus, 
although it can be agreed that rosuvastatin low-
ered the risk of cardiovascular disease in this 
study, the methods used to report the results over-
estimate the strength of the association.
Clarence E. Davis, Ph.D.
University of North Carolina 
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To the Editor: Ridker et al. used conventional 
Kaplan–Meier analyses to describe the probabil-
ity of the occurrence of major cardiovascular events 
over time. Such analyses assume that the event of 
interest is as likely to occur in the future in pa-
tients for whom data have been censored as in 
those remaining in the trial. This assumption is 
obviously not the case for patients who died from 
noncardiovascular causes. The censoring of “com-
peting deaths” estimates the actuarial rather than 
the actual cumulative incidence.1-3 Hence, the ab-
solute difference in risk is inflated, and the re-
spective number of patients who would need to 
be treated to prevent one occurrence of the end 
point becomes too low. If we assume that there 
was a 30% relative overestimation3 of the actual 
cumulative incidence, the number needed to treat 
increases by the same magnitude, from 95 to 124. 
Since the number of competing deaths from non-
cardiovascular causes might increase with time, 
the difference may particularly affect the projected 
numbers needed to treat at 4 and 5 years. A com-
peting-risk method would have been preferable 
to determine the actual cumulative incidence and 
estimates of the number who would need to be 
treated.
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The authors reply: We agree with Gibbons that 
improved compliance with current guidelines re-
mains important for primary prevention of car-
diovascular disease. However, in our trial, the 
5-year number needed to treat for nonsmokers, 
patients without hypertension or the metabolic 
syndrome, and those with low Framingham scores 
are all similar to or smaller than the 5-year values 
of 50 to 60 previously reported for statins among 
white men with hyperlipidemia.
Full prescribing data for rosuvastatin among 
Asians were not available in 2002. Thus, Fugh-
Berman is correct that Asian participation was 
marginal. The safety of rosuvastatin has subse-
quently been established and the 20-mg dose ap-
proved for patients of Asian descent.
The calculations by Chan et al. are incorrect 
partly because they do not account for deaths from 
vascular causes, such as aneurysm rupture. Fur-
thermore, because we prespecified very strict con-
firmation criteria, many out-of-hospital deaths 
from cardiovascular causes were classified as be-
ing from noncardiovascular causes for trial pur-
poses. On the basis of these strict criteria, the 
numbers of confirmed deaths from cardiovascu-
lar causes were 35 in the rosuvastatin group and 
43 in the placebo group, with a hazard ratio in 
the rosuvastatin group of 0.82 (95% CI, 0.52 to 
1.27), which was similar to the reported hazard 
ratio for death from any cause of 0.80 (95% CI, 
0.67 to 0.97). Our trial is consistent with the no-
tion that achieving very low levels of high-sensi-
tivity C-reactive protein and LDL cholesterol can 
enhance statin benefits1,2 — analyses that will 
interest Chan et al., along with Jenny-Avital. As 
anticipated, the absolute risk of a cardiovascular 
event increased with increased levels of high-
sensitivity C-reactive protein and decreased with 
decreased levels.
We partially disagree with Mak and Chan. If 
the “protective” effect on diabetes incidence re-
ported in WOSCOPS is treated as hypothesis-
generating, then a summary of published hypoth-
esis-testing trials demonstrates that all statins 
modestly increase the risk of diabetes, with no 
heterogeneity according to potency. In our study, 
many of the patients in whom diabetes devel-
oped were obese or had an impaired fasting 
glucose level, groups in which large reductions 
in vascular events were associated with rosuva-
statin.
The independent data and safety monitoring 
board for our trial followed rigorous principles3 
in its prespecification that early termination of the 
study because of an observed benefit would re-
quire proof beyond a reasonable doubt. Members 
of the board were experienced in monitoring pub-
licly and privately funded trials and viewed the 
trial’s prespecified statistical boundary as only one 
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component required for proof. Although the for-
mal statistical boundary was conservative and 
evaluated only after accrual of ample data, the 
board elected to continue the trial for an addi-
tional 6 months after the boundary was crossed. 
Data that were accrued thereafter independently 
confirmed both the magnitude and statistical sig-
nificance of the apparent benefit. We thus respect-
fully disagree with Pierard and Davis. The board 
appropriately protected the interests of society and 
the trial participants and provided a valid estimate 
of the treatment effect.4
The evaluation by Koller et al. ignores the sig-
nificant reduction in death from any cause that 
we observed. If death from any cause is added to 
our primary composite outcome (a standard ap-
proach to account for competing risks), then the 
absolute risk difference increases and the num-
ber needed to treat declines.
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Obesity and Risk of Death
To the Editor: A challenging issue with the 
study reported on by Pischon et al. (Nov. 13 is-
sue)1 is where to measure the waist. The accepted 
standard for measuring the waist circumference 
put forth by the third National Health and Nutri-
tion Examination Surveys (NHANES III) proto-
col,2 as noted by Mahley in the Williams Textbook 
of Endocrinology,3 is: “to measure waist circumfer-
ence, locate the top of the right iliac crest. Place 
a measuring tape in a horizontal plane around 
the abdomen at the level of the iliac crest. Before 
reading the tape measure, ensure that the tape is 
snug but does not compress the skin and is par-
allel to the floor. Measurement is made at the end 
of a normal expiration.” However, Pischon et al. 
report that in their study, “waist circumference 
was measured either at the narrowest circumfer-
ence of the torso or at the midpoint between the 
lower ribs and the iliac crest.” International ac-
ceptance of measurement tools is paramount.
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To the Editor: Pischon et al. support the use of 
waist circumference or waist-to-hip ratio in addi-
tion to body-mass index (BMI) in assessing the 
risk of death. Engeland et al. found that height is 
inversely associated with mortality among men 
and to some degree among women.1 My recent 
study2 and a meta-analysis,3 both of which used 
cross-sectional data, provide support for the su-
periority of measures of central obesity — espe-
cially waist-to-height ratio — over BMI for dis-
criminating the presence or absence of cardiologic 
and metabolic risk factors. Pischon et al. appro-
priately adjusted for height when calculating the 
mortality risk associated with anthropometric in-
dexes. It would be helpful if the authors would 
determine the relative risk of death according to 
waist-to-height ratio and its comparison with oth-
er anthropometric data. For a fair comparison, 
height should not be adjusted for other studied 
anthropometric indexes.
Pischon et al. indicated that they observed no 
significant association between hip circumference 
and mortality risk. Larger hip circumference was 
shown to be an independent predictor of a lower 
mortality rate in a Swedish female cohort.4 Did 
Pischon et al. confirm that?
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